We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
News

Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium

Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
News

Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cenix BioScience GmbH, has announced that it is growing its R&D operations by establishing a new subsidiary in Flanders, Belgium.

The new subsidiary company, named Cenix BioScience BVBA, will be wholly owned by its Dresden-based parent, and will help accelerate the development of the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi. Through these programs, Cenix is working to improve the in vivo applicability of siRNA technology by testing novel delivery solutions including its own proprietary DARE™ technology.

The expansion comes as part of a major growth and diversification initiative ongoing since 2008 to broaden the company's range of activities beyond the cell-based RNAi services that have established Cenix as a global leader in various applications of RNAi screening over the past 11 years.

“We are very excited to start this important new phase in our company’s development,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “This opportunity comes as the result of many years of hard work by past and present staff. It also arises at a particularly strategic time in the maturation of the RNAi field, which we are eager to help drive further forward in the years to come, now through both our original Dresden team and our new Flanders unit.”
Advertisement